Answers are grounded in this paper and cite their sources.
Anti-angiogenic therapies (AAT), including monoclonal antibodies (MAB) and tyrosine kinase inhibitors (TKI), have become a cornerstone in the management of advanced or treatment-refractory malignancies. Despite their proven efficacy, these agents can cause significant adverse effects related to impaired vascular repair and wound healing. Among the rare but serious complications, tracheoesophageal fistula (TEF) has emerged as a clinically relevant and potentially fatal event. This review analyzes the existing literature to explore the association between AAT and TEF formation, emphasizing the underlying mechanisms, risk factors, and clinical implications. Evidence suggests that inhibition of vascular endothelial growth factor signaling compromises endothelial regeneration, particularly in tissues previously exposed to radiotherapy, inflammation, or surgical manipulation. Bevacizumab-related TEFs have been primarily reported in patients with lung cancer undergoing multimodal treatment, while TKI-associated cases, most often linked to Lenvatinib or Cabozantinib, have occurred in thyroid cancer with tracheoesophageal invasion or rapid tumor regression. No TEF has been described in treatment-naïve or neoadjuvant settings, indicating a safer profile in the absence of pre-existing local iatrogenic damage. Overall, TEF should be regarded as an extreme manifestation of wound- healing impairment rather than a random event. Careful patient selection, multidisciplinary assessment, and vigilant clinical monitoring are essential to balance therapeutic efficacy with patient safety. Further research is warranted to elucidate the biological mechanisms underlying this complication and optimize treatment strategies for high-risk patients.
No takes yet. Share an insight, caveat, or question.
Nassih et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: